RxDoctor Payments Data

Sherri Thomas, MD

Family Medicine · Tulsa, OKNPI 1902877749

Payments from drug & device makers

$4,541in general payments, 2019–2025

Across 253 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$597
  • Pfizer$422
  • Lilly USA, LLC$388
  • Abbott$227
  • Astellas Pharma US Inc$197
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,51699%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,541 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$56,950
Medicare patients
220
Services billed
1,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide66$70,346
OzempicSemaglutide41$38,784
EliquisApixaban40$38,211
TrulicityDulaglutide28$31,667
JardianceEmpagliflozin23$27,518
MyrbetriqMirabegron35$22,131
Atorvastatin Calcium317$9,389
Combivent RespimatIpratropium/Albuterol Sulfate12$5,495
Pravastatin Sodium174$4,848
Metoprolol Succinate155$4,691
Losartan Potassium287$4,456
Potassium Chloride151$4,028
Amlodipine Besylate350$3,787
Lisinopril271$3,491
Levothyroxine Sodium353$2,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$388$102,01394 claims
Novo NordiskOzempic$597$38,78441 claims
PfizerEliquis$422$38,21140 claims
Boehringer IngelheimJardiance, Combivent Respimat$121$33,01335 claims
Astellas Pharma US IncMyrbetriq$197$22,13135 claims
AbbVieSynthroid$1,032$2,37529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →